-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

876 Mapping the Human Bone Marrow in Myeloproliferative Neoplasia Using Spatial Transcriptomics

Program: Oral and Poster Abstracts
Type: Oral
Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: New Insights into The Biology of Myeloproliferative Syndromes
Hematology Disease Topics & Pathways:
Research, Translational Research, Diseases, Myeloid Malignancies
Monday, December 9, 2024: 4:00 PM

Rosalin Cooper1,2*, Emily Thomas3*, Dawood Muhammad1,3*, Carlo Pescia1*, Anna Sozanska2*, Oliver McCallion4*, Hosuk Ryou3*, Renuka Teague4*, Alan King Lun Liu2*, Joanna Hester4*, Fadi Issa4*, Bethan Psaila, MD, PhD5, Adam J Mead, PhD, MRCP, FRCPath6, Jens Rittscher3*, Dan Woodcock4* and Daniel Royston, DPhil, FRCPath, MBBChir1,2

1Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, United Kingdom
2Oxford University Hospitals, Oxford, United Kingdom
3Institute of Biomedical Engineering, University of Oxford, Oxford, United Kingdom
4Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom
5Medical Research Council (MRC) Weatherall Institute of Molecular Medicine (WIMM), University of Oxford, Oxford, ENG, United Kingdom
6Medical Research Council (MRC) Weatherall Institute of Molecular Medicine (WIMM), University of Oxford, Oxford, United Kingdom

Background: Myeloproliferative neoplasms (MPNs) are a group of myeloid malignancies characterised by activation of JAK-STAT signalling and increased production of haematopoietic stem and progenitor (HSPC)-derived populations. Whilst the molecular drivers of MPN are well-defined, the clinical phenotype is heterogeneous and clinical course highly variable. Whilst most patients have chronic-phase disease - most commonly essential thrombocythemia (ET) or polycythaemia vera (PV) - some develop myelofibrosis (MF) which is associated with a significantly worse prognosis. Interplay between immune, stromal and megakaryocyte populations is thought to drive bone marrow fibrosis. However, how these cellular populations underpin this process is not yet fully defined. Emerging spatial transcriptomic (ST) platforms provide in-situ profiling with up to subcellular resolution and offer novel opportunities for characterising tissue microenvironments. We use the 10x Xenium platform to map the human bone marrow across large cohort of archival diagnostic tissue, for the first time providing whole section in-situ descriptions of the bone marrow microenvironment at single cell resolution. This approach has the potential for providing novel insights into mechanisms underpinning myelofibrosis and to detect spatial and microenvironmental features characteristic the earliest stages of MPN. Integration of these data with H&E morphology provides opportunities for the development of artificial intelligence (AI)-based models with the potential for genuine translation into clinical workflows to support and enhance clinical diagnostics.

Method: We developed a workflow for generating high-quality spatially resolved data from human archival formalin-fixed paraffin-embedded bone marrow trephine (BMT) material. We perform Xenium analysis on a large (n = 30) cohort of patients with MPN (n = 11 MF, n = 3 PrePMF, n = 8 ET, n = 3 PV, and n = 5 normal BMTs). We integrate the ST output with H&E morphology, demonstrating how this supports cellular segmentation and regional annotation. We develop a graph neural network (GNN) pipeline to facilitate the application of a machine learning model to our ST data.

Results: We identify a total of 6,304,337 BM cells from BMTs from 30 patients, including lymphocyte (CD4+ and CD8+), erythroid, megakaryocyte, endothelial, antigen presenting cell (dendritic cells, monocytes and macrophages), granulocyte, and haematopoietic stem and progenitor cell (HSPC) groups. We identify distinct mesenchymal stromal cell (MSC) groups including osteogenic-MSC and osteoblasts enriched within the endosteal niche, and an adipocytic MSC group enriched within intertrabecular regions. We systematically characterise the endosteal, peritrabecular and intertrabecular microenvironments. We identify and map HSPC and progenitor populations, defining microenvironmental perturbation characteristic of MPN. We quantitively describe the cellular composition of the human marrow, demonstrating how whole-trephine cellular abundance distinguishes both MF and PrePMF patients from those with non-fibrotic MPN (ET and PV) and normal marrows. We find that erythroid and megakaryocyte groups are expanded with increased cell-cell adjacency in MF, potentially reflecting megakaryocyte bias of the shared precursor. Differential expression analysis identifies upregulation of extracellular matrix (ECM)-associated transcripts across nearly all lineages in MF and PrePMF versus the normal marrow, but not in non-fibrotic MPN. Finally, we apply a graph neural network (GNN) approach to our spatially resolved ST-BMT dataset, generating a model which can with high confidence distinguish MPN from normal marrow. This approach furthermore allows high-resolution characterisation of the cellular microenvironmental and spatial features which define MPN.

Conclusions: We present the first whole-section spatial atlas of the human marrow at single cell resolution, demonstrating how ST approaches can provide novel insights into both normal marrow homeostasis and mechanisms underpinning disease progression in MPN. We also demonstrate the opportunities afforded by spatially-resolved single cell data for generating AI-based models with potential for genuine translational applicability, supporting early and accurate diagnosis and prognostication.

Disclosures: Psaila: Blueprint Medicines: Consultancy; Incyte: Consultancy, Research Funding; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees; University of Oxford: Patents & Royalties: 2203947.3; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy; Alethiomics: Consultancy, Current equity holder in private company, Research Funding. Mead: Ionis: Consultancy, Honoraria; Medscape: Honoraria; Karyopharm: Consultancy, Honoraria; GSK: Consultancy, Honoraria, Research Funding; Alethiomics: Consultancy, Current equity holder in private company, Current holder of stock options in a privately-held company, Research Funding; Incyte: Consultancy, Honoraria; Galecto: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; Morphosys: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Roche: Research Funding. Rittscher: Ground Truth Labs Ltd.: Current equity holder in private company. Royston: Johnson & Johnson: Consultancy; Ground Truth Labs Ltd.: Consultancy.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH